ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2026
Anxiety and depression in emerging adults: The STAND program as a model of scalable screening and intervention.
Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Population-based RCT of a digital cognitive-behavioural guided self-help intervention for anxiety, depression and eating disorders in college students.Nature human behaviour · 2026Trial
- Improving Digital Measurement-Based Care Within Emerging Adult Mental Health Care Pathways: Protocol for a Co-Design Phase Embedded in a Multimethod Rapid Learning Health System Study.JMIR research protocols · 2026Article
- The puzzle of heterogeneity: an introduction to part II.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Trajectories of mental health and mental illness: where we are now and where we go next.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Psychobiotics at the Frontiers of Neurodegenerative and Neuropsychiatric Research.Microorganisms · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Depressive and anxiety disorders are highly and increasingly prevalent among 18 to 25 years olds as individuals emerge into adulthood. If untreated, these conditions have potentially serious consequences for social, academic and occupational functioning and confer risk for various mental health and health conditions, rendering prevention and treatment of paramount importance. After reviewing the evidence for prevalence, chronicity and cost of anxiety and depression in this transitional developmental period, we present evidence for psychotherapeutic and pharmacological interventions that can effectively prevent and treat depression and anxiety. Next, we describe the major barriers to prevention and treatment in young adults that result in significant unmet need. To address this mental health gap, we describe a digitally-supported, stratified stepped care system designed to overcome barriers while also personalizing the prevention and treatment of anxiety and depression, called Screening and Treatment for Anxiety and Depression (STAND). We conclude with challenges in this field of research and future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.